Literature DB >> 204740

Seroepidemiological investigation of patients and family contacts in an epidemic of hepatitis A.

G G Frösner, L R Overby, B Flehmig, H J Gerth, H Haas, R H Decker, C M Ling, A J Zuckerman, H R Frösner.   

Abstract

Serial blood and faecal samples were collected from patients and family contacts during an outbreak of hepatitis A in a village and tested by a solid-phase competitive type radioimmunoassay for hepatitis A antigen and hepatitis A antibody. The amount and duration of excretion of hepatitis A antigen was correlated with the severity of the illness. In 2 severe clinical cases, hepatitis A antigen was demonstrated in faecal extracts 11 days before the onset of jaundice and continuing for 10 days thereafter, with maximum shedding during the late incubation period. Faecal antigen was demonstrated in low concentrations for only 2 days in a patient with mild disease and in a person with subclinical infection. There was an inverse correlation between the incidence of infection and prevalence of hepatitis A antibody and age. Of 24 infections, 19 (79%) occurred in persons in the age group 0 to 20 years, a group in which only 6% of individuals had pre-existing antibody. Hepatitis A antibody was present in the serum of 3 persons in low titres of 1:20 to 1:40 on the day jaundice developed. The antibody titres increased very rapidly during the following 2 weeks of illness and slowly during the following months, reaching titres of 1:900 to 1:3500. In a separate study, a mean antibody titre of 1:591 was found in 13 patients, 12 years after clinical hepatitis A with jaundice.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 204740     DOI: 10.1002/jmv.1890010303

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  24 in total

1.  Shifts in the rates and levels of antibody to hepatitis A virus associated with hepatitis A infection in children's communities.

Authors:  S A Prikazchikov; M S Balayan
Journal:  Eur J Epidemiol       Date:  1987-12       Impact factor: 8.082

2.  Studies on antibody to hepatitis A virus in children and adults in London.

Authors:  V Damjanovic; M Ross; W Brumfitt
Journal:  Infection       Date:  1979       Impact factor: 3.553

3.  Characterization and classification of virus particles associated with hepatitis A. II. Type and configuration of nucleic acid.

Authors:  G Siegl; G G Frösner
Journal:  J Virol       Date:  1978-04       Impact factor: 5.103

Review 4.  Clinical development of a new inactivated hepatitis A vaccine.

Authors:  E Vidor; B Fritzell; S Plotkin
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

5.  Tourist hepatitis, antibodies to hepatitis A virus and immune serum globulin prophylaxis.

Authors:  S Iwarson; G Frösner; G Norkrans
Journal:  Infection       Date:  1978       Impact factor: 3.553

6.  Decrease in incidence of hepatitis A infections in Germany.

Authors:  G Frösner; H Willers; R Müller; D Schenzle; F Deinhardt; W Höpken
Journal:  Infection       Date:  1978       Impact factor: 3.553

7.  Serodiagnosis of viral hepatitis A by a modified competitive binding radioimmunoassay for immunoglobulin M anti-hepatitis A virus.

Authors:  D W Bradley; H A Fields; K A McCaustland; J E Maynard; R H Decker; R Whittington; L R Overby
Journal:  J Clin Microbiol       Date:  1979-01       Impact factor: 5.948

8.  Specific serological diagnosis of viral hepatitis.

Authors:  A J Zuckerman
Journal:  Br Med J       Date:  1979-07-14

9.  Serological hepatitis A virus infections and ratio of clinical to serological infections in a controlled trial of pre-exposure prophylaxis with immune serum globulin.

Authors:  J D Kark; S Bar-Shany; S Shor; L Merlinski; E Nili
Journal:  J Epidemiol Community Health       Date:  1985-06       Impact factor: 3.710

10.  Hepatitis A-virus in cell culture: I. propagation of different hepatitis A-virus isolates in a fetal rhesus monkey kidney cell line (Frhk-4).

Authors:  B Flehmig
Journal:  Med Microbiol Immunol       Date:  1980       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.